Your browser is no longer supported. Please, upgrade your browser.
TTPH Tetraphase Pharmaceuticals, Inc. weekly Stock Chart
TTPH [NASD]
Tetraphase Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-29.71 Insider Own0.61% Shs Outstand2.89M Perf Week-8.10%
Market Cap6.56M Forward P/E- EPS next Y-10.29 Insider Trans0.00% Shs Float2.89M Perf Month-29.72%
Income-80.20M PEG- EPS next Q-5.25 Inst Own17.30% Short Float3.75% Perf Quarter-53.12%
Sales10.00M P/S0.66 EPS this Y47.80% Inst Trans-41.79% Short Ratio1.01 Perf Half Y-84.35%
Book/sh9.80 P/B0.23 EPS next Y61.20% ROA-88.00% Target Price1.50 Perf Year-93.55%
Cash/sh8.48 P/C0.27 EPS next 5Y- ROE-152.10% 52W Range2.26 - 36.00 Perf YTD-89.96%
Dividend- P/FCF- EPS past 5Y5.00% ROI-67.90% 52W High-93.69% Beta2.17
Dividend %- Quick Ratio2.50 Sales past 5Y12.50% Gross Margin81.20% 52W Low0.44% ATR0.30
Employees119 Current Ratio2.70 Sales Q/Q175.00% Oper. Margin- RSI (14)33.91 Volatility9.80% 9.33%
OptionableYes Debt/Eq0.00 EPS Q/Q18.80% Profit Margin- Rel Volume0.95 Prev Close2.49
ShortableYes LT Debt/Eq0.00 EarningsNov 12 AMC Payout- Avg Volume107.30K Price2.27
Recom2.70 SMA20-14.07% SMA50-37.98% SMA200-81.31% Volume102,088 Change-9.02%
Oct-31-19Upgrade Gabelli & Co Hold → Buy
Jan-07-19Resumed B. Riley FBR Buy $3
Sep-06-18Upgrade WBB Securities Speculative Buy → Buy $7
Feb-22-18Initiated WBB Securities Speculative Buy $6
Feb-14-18Reiterated Stifel Buy $13 → $6
Feb-14-18Reiterated H.C. Wainwright Buy $17 → $6
Feb-12-18Initiated B. Riley FBR, Inc. Buy $11
Nov-06-17Reiterated H.C. Wainwright Buy $15 → $17
Oct-09-17Reiterated Stifel Buy $13 → $13
Aug-28-17Initiated Piper Jaffray Overweight $14
Jul-26-17Upgrade Stifel Hold → Buy $8 → $15
Jul-11-17Initiated H.C. Wainwright Buy $15
Mar-09-17Reiterated Stifel Hold $5 → $7
May-13-16Reiterated Wedbush Outperform $8 → $4
May-13-16Downgrade Gabelli & Co Buy → Hold $7
Nov-19-15Upgrade Sun Trust Rbsn Humphrey Neutral → Buy
Sep-09-15Downgrade Stifel Buy → Hold
Sep-09-15Downgrade Robert W. Baird Outperform → Neutral $41 → $10
Sep-09-15Downgrade Nomura Buy → Neutral
Sep-09-15Downgrade Needham Buy → Hold
Dec-02-19 08:40PM  Edited Transcript of TTPH earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 05:15PM  Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Tetraphase Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Developments Business Wire
Nov-05-19 08:00AM  Tetraphase Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call Business Wire
Nov-01-19 04:18PM  Tetraphase Pharmaceuticals Announces Completion of $8 Million Registered Direct Offering Priced At-the-Market Business Wire -6.27%
Oct-30-19 08:00AM  Tetraphase Pharmaceuticals Announces $8 Million Registered Direct Offering Priced At-the-Market Business Wire
Sep-26-19 07:00AM  Tetraphase Pharmaceuticals Announces Reverse Stock Split Business Wire -9.23%
Sep-25-19 07:00AM  Tetraphase Pharmaceuticals to Present XERAVA (Eravacycline) Data at IDWeek 2019 Business Wire -5.07%
Sep-22-19 08:06AM  Edited Transcript of TTPH earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-12-19 01:11PM  What Kind Of Shareholder Owns Most Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stock? Simply Wall St. +19.44%
Aug-09-19 03:23PM  Tetraphase Pharmaceuticals Inc (TTPH) Q2 2019 Earnings Call Transcript Motley Fool -9.66%
Aug-08-19 05:55PM  Tetraphase Pharmaceuticals (TTPH) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM  Tetraphase Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate Developments Business Wire
Jul-25-19 10:33AM  Earnings Preview: Tetraphase Pharmaceuticals (TTPH) Q2 Earnings Expected to Decline Zacks
Jun-24-19 07:00AM  New Studies Highlight Activity of XERAVA Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens Business Wire
Jun-17-19 03:14PM  Edited Transcript of TTPH earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-13-19 08:44PM  Robbins Arroyo LLP: Tetraphase Pharmaceuticals, Inc. (TTPH) Accused of Misleading Shareholders Business Wire
02:04PM  What You Should Know About Tetraphase Pharmaceuticals, Inc.'s (NASDAQ:TTPH) Financial Strength Simply Wall St.
07:44AM  The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes Benzinga
07:00AM  Tetraphase Pharmaceuticals Highlights Data at Upcoming American Society for Microbiology Microbe 2019 Annual Meeting Business Wire
Jun-12-19 04:01PM  Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA (Eravacycline) Commercial Opportunity Business Wire
Jun-10-19 07:00AM  Tetraphase Pharmaceuticals Announces New XERAVA (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting Business Wire +6.19%
May-29-19 07:00AM  Tetraphase Pharmaceuticals to Present Data at the 39th Annual Meeting of the Surgical Infection Society Business Wire +26.79%
May-09-19 09:23AM  Tetraphase Pharmaceuticals Inc (TTPH) Q1 2019 Earnings Call Transcript Motley Fool -6.54%
May-08-19 05:35PM  Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:27PM  Tetraphase: 1Q Earnings Snapshot Associated Press
04:01PM  Tetraphase Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Corporate Developments Business Wire
May-06-19 04:13AM  Edited Transcript of TTPH earnings conference call or presentation 14-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
May-02-19 07:00AM  Tetraphase Pharmaceuticals to Present Data at the 22nd Annual MAD-ID Meeting Business Wire
May-01-19 07:03AM  Tetraphase Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call Business Wire
Apr-30-19 07:00AM  Tetraphase Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire
Apr-28-19 10:08AM  Easy Come, Easy Go: How Tetraphase Pharmaceuticals (NASDAQ:TTPH) Shareholders Got Unlucky And Saw 90% Of Their Cash Evaporate Simply Wall St.
Apr-25-19 10:33AM  Will Tetraphase Pharmaceuticals (TTPH) Report Negative Q1 Earnings? What You Should Know Zacks
Apr-08-19 07:00AM  Tetraphase Pharmaceuticals to Present Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases Business Wire
Apr-05-19 06:22PM  Robbins Arroyo LLP: Tetraphase Pharmaceuticals, Inc. (TTPH) Accused of Misleading Shareholders Business Wire
Apr-03-19 08:00AM  Tetraphase Pharmaceuticals Presents Preclinical Data on TP-2846, a Novel Drug Candidate for Acute Myeloid Leukemia Business Wire
Apr-01-19 04:03PM  Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Mar-15-19 02:13AM  Tetraphase Pharmaceuticals (TTPH) Q4 2018 Earnings Conference Call Transcript Motley Fool +8.46%
Mar-14-19 04:20PM  Tetraphase: 4Q Earnings Snapshot Associated Press
04:03PM  Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Achievements and Key 2019 Milestones Business Wire
02:30PM  Tetraphase Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-19 04:03PM  Tetraphase Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call Business Wire +8.06%
Feb-27-19 04:30PM  Tetraphase Pharmaceuticals to Present Data on Preclinical Activity of TP-2846 in Acute Myeloid Leukemia Business Wire
Jan-28-19 09:45PM  Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Tetraphase Pharmaceuticals, Inc. (TTPH) and Encourages TTPH Investors to Contact the Firm GlobeNewswire
Jan-23-19 02:40PM  Robbins Arroyo LLP: Shareholders Allege That Tetraphase Pharmaceuticals, Inc. (TTPH) Misled Shareholders Business Wire
Jan-15-19 07:20AM  New Research: Key Drivers of Growth for Tetraphase Pharmaceuticals, Olympic Steel, Belden, KAR Auction Services, BWX Technologies, and Sparton Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Dec-05-18 06:30AM  Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-29-18 07:50AM  Report: Exploring Fundamental Drivers Behind Resonant, Constellation Brands, Masimo, Tetraphase Pharmaceuticals, LivaNova, and Penumbra New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-08-18 09:17PM  Edited Transcript of TTPH earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
06:10PM  Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:06PM  Tetraphase: 3Q Earnings Snapshot Associated Press
04:01PM  Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-07-18 06:00AM  Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Nov-01-18 04:01PM  Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call GlobeNewswire +8.78%
Oct-25-18 01:12PM  War against the superbugs: Mass. biotechs step up to fight antibiotic resistance American City Business Journals
Oct-23-18 03:34PM  Is Tetraphase Pharmaceuticals Incs (NASDAQ:TTPH) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
06:30AM  Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analysis of Phase 3 Trials Demonstrating Efficacy of XERAVA (eravacycline) in Obese and Renally Impaired Patients with Complicated Intra-Abdominal Infections GlobeNewswire
Oct-22-18 07:20AM  Consolidated Research: 2018 Summary Expectations for Vuzix, BCE, Tetraphase Pharmaceuticals, T2 Biosystems, TPG Specialty Lending, and Jianpu Technology Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-11-18 04:01PM  Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA in the United States GlobeNewswire
Oct-08-18 06:30AM  Tetraphase Pharmaceuticals Announces Presentation of Positive Data from Phase 3 Trials of XERAVA (eravacycline) and Multiple-Ascending Dose Trial of TP-6076 at IDWeek 2018 GlobeNewswire
Oct-04-18 08:37AM  Options Traders Expect Huge Moves in Tetraphase (TTPH) Stock Zacks
Sep-28-18 04:01PM  Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-25-18 12:30PM  DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Sep-24-18 06:24PM  Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. (TTPH) GlobeNewswire
04:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tetraphase Pharmaceuticals, Inc. - TTPH ACCESSWIRE
04:01PM  Tetraphase Pharmaceuticals to Present at the Cantor Global Healthcare Conference GlobeNewswire
Sep-23-18 02:00PM  CLASS ACTION UPDATE for RMTI, TTPH, HMNY and GDS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Sep-21-18 06:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tetraphase Pharmaceuticals, Inc. - TTPH ACCESSWIRE -7.59%
03:17PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZN, RMTI, TTPH, HMNY, PM and QRTEA GlobeNewswire
10:20AM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. - TTPH ACCESSWIRE
10:00AM  DEADLINE ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. (TTPH) and Lead Plaintiff Deadline September 25, 2018 GlobeNewswire
Sep-20-18 05:27PM  SHAREHOLDER ALERT: ZN RMTI TTPH ABBV HMNY GDS PVG OPK USAT TRCO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
02:23PM  TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
01:23PM  EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. TTPH Business Wire
01:08PM  Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections GlobeNewswire
Sep-19-18 11:00AM  Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. (TTPH) Business Wire
06:00AM  Tetraphase Pharmaceuticals to Present XERAVA (Eravacycline) and TP-6076 Data at IDWeek 2018 GlobeNewswire
Sep-18-18 07:59PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vuzix, Tetraphase, and LogMeIn and Encourages Investors to Contact the Firm GlobeNewswire -5.23%
07:34PM  The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. (TTPH) Business Wire
11:15AM  CLASS ACTION UPDATE for SBGI, TTPH and HMNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Sep-17-18 10:08AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. (TTPH) and Lead Plaintiff Deadline - September 25, 2018 ACCESSWIRE
10:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, FIZZ, RMTI, TTPH and FB GlobeNewswire
Sep-16-18 11:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZN, RMTI, TTPH, HMNY and GDS GlobeNewswire
Sep-14-18 08:57PM  Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Tetraphase Pharmaceuticals, Inc. Investors (TTPH) GlobeNewswire
07:57PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tetraphase Pharmaceuticals, Inc. - TTPH GlobeNewswire
12:45PM  SHAREHOLDER ALERT: PM QRTEA LOGM NLSN ACAD RMTI TTPH FB GDS SKX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Sep-13-18 05:10PM  Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Tetraphase Pharmaceuticals, Inc. Investors Business Wire
12:30PM  CLASS ACTION UPDATE for PDD, SBGI and TTPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Sep-12-18 07:59PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tetraphase Pharmaceuticals, Inc. - TTPH ACCESSWIRE
05:46PM  Lifshitz & Miller LLP Announces Investigation of American Express Company, GDS Holdings Limited, Lannett Company, Inc., Mednax, Inc., Menlo Therapeutics Inc., Papa John's International, Inc., Tetraphase Pharmaceuticals, Inc. and Zion Oil & Gas, Inc. PR Newswire
02:36PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FIZZ, RMTI, TTPH, ABBV and GDS GlobeNewswire
10:29AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. (TTPH) and Lead Plaintiff Deadline - September 25, 2018 ACCESSWIRE
Sep-09-18 11:30AM  SHAREHOLDER ALERT: PDD AMPE NVRO PZZA ZN SBGI ACAD FIZZ TTPH FB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Sep-08-18 07:18AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tetraphase Pharmaceuticals, Inc. - TTPH ACCESSWIRE
Sep-07-18 03:14PM  Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Tetraphase Pharmaceuticals, Inc. Investors GlobeNewswire
Sep-06-18 01:00PM  CLASS ACTION UPDATE for RMTI, TTPH and FB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:01AM  SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. (TTPH) & Lead Plaintiff Deadline September 25, 2018 ACCESSWIRE
Sep-05-18 05:31PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GLCNF GLNCY, MRCY, FPI, RMTI and TTPH GlobeNewswire -7.45%
05:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tetraphase Pharmaceuticals, Inc. - TTPH ACCESSWIRE
Sep-04-18 06:33PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tetraphase Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dumas JacquesChief ScientificOfficerJan 08Sale1.607,49711,9950Jan 10 05:18 PM